ノイラミニダーゼ阻害薬
WordNet
- limit, block, or decrease the action or function of; "inhibit the action of the enzyme"; "inhibit the rate of a chemical reaction"
- control and refrain from showing; of emotions, desires, impulses, or behavior (同)bottle up, suppress
- limit the range or extent of; "Contact between the young was inhibited by strict social customs"
- a substance that retards or stops an activity
PrepTutorEJDIC
- 〈感情・欲望・行動・作用など〉‘を'抑制する / (…しないように)〈人〉‘を'抑制する,妨げる《+『名』+『from』+『名』(do『ing』)》
- 抑制する人(物) / 化学反応抑制剤
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/12/24 04:03:04」(JST)
[Wiki en表示]
Neuraminidase inhibitors are a class of drugs which block the neuraminidase enzyme. They are commonly used as antiviral drugs because they block the function of viral neuraminidases of the influenza virus, by preventing its reproduction by budding from the host cell. Oseltamivir (Tamiflu) a prodrug, Zanamivir (Relenza), Laninamivir (Inavir), and Peramivir belong to this class. Unlike the M2 inhibitors, which work only against the influenza A, neuraminidase inhibitors act against both influenza A and influenza B.[1][2][3][4] The neuraminidase inhibitors oseltamivir and zanamivir were approved in the US and Europe for treatment and prevention of influenza A and B.
The efficacy was highly debated in recent years.[citation needed] The benefits of neuraminidase inhibitors in those who are otherwise healthy do not appear to outweigh its risks.[citation needed] The combination of diagnostic uncertainty, the risk for virus strain resistance, possible side effects and financial cost outweigh the small benefits of oseltamivir or zanamivir for the prophylaxis and treatment of healthy individuals.[5] No benefit of treatment, on hospitalization, complications or risk of death has been found in randomized trials in those people at high risk for complications or the elderly.[5][6][7] The United States Centers for Disease Control continues to recommend the use of oseltamavir treatment for people at high risk for complications and the elderly and those at lower risk who present within 48 hours of first symptoms of infection.[8]
Common side effects include nausea and vomiting. For oseltamivir there were neuropsychiatric effects and for zanamivir bronchoconstriction occurred.
Contents
- 1 Specific neuraminidase inhibitors
- 1.1 Structures of the Viral neuraminidase inhibitors in use
- 2 Natural products
- 3 See also
- 4 References
Specific neuraminidase inhibitors
- Laninamivir
- Oseltamivir (Tamiflu)
- Peramivir
- Zanamivir (Relenza)
Structures of the Viral neuraminidase inhibitors in use
Viral neuraminidase inhibitors in use
|
|
|
|
| Zanamivir |
Oseltamivir |
Peramivir |
Laninamivir |
Natural products
- Cyanidin-3-sambubioside (Extracted from black elderberry)[9]
See also
- Discovery and development of Neuraminidase Inhibitors
References
- ^ Smith, B. J.; McKimm-Breshkin, J. L.; McDonald, M.; Fernley, R. T.; Varghese, J. N.; Colman, P. M. (2002). "Structural Studies of the Resistance of Influenza Virus Neuramindase to Inhibitors". Journal of Medicinal Chemistry 45 (11): 2207. doi:10.1021/jm010528u. PMID 12014958.
- ^ Gubareva, Larisa V (2004). "Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors". Virus Research 103 (1-2): 199–203. doi:10.1016/j.virusres.2004.02.034.
- ^ This flash animation shows the mode of action of oseltamivir (Tamiflu). pharmasquare.org
- ^ Replication of influenza virus. mvm.ed.ac.uk
- ^ a b Jefferson, Tom; Michiels, Barbara; Van Puyenbroeck, Karolien; Verhoeven, Veronique; Vermeire, Etienne; Coenen, Samuel (2013). "The Value of Neuraminidase Inhibitors for the Prevention and Treatment of Seasonal Influenza: A Systematic Review of Systematic Reviews". PLoS ONE 8 (4): e60348. doi:10.1371/journal.pone.0060348. ISSN 1932-6203. PMC 3614893. PMID 23565231.
- ^ Ebell, MH; Call, M; Shinholser, J (April 2013). "Effectiveness of oseltamivir in adults: a meta-analysis of published and unpublished clinical trials". Family practice 30 (2): 125–33. doi:10.1093/fampra/cms059. PMID 22997224.
- ^ Jefferson T, Jones MA, Doshi P, et al. (April 2014). "Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children". Cochrane Database Syst Rev 4: CD008965. doi:10.1002/14651858.CD008965.pub4. PMID 24718923.
- ^ "CDC Online Newsroom - "Have You Heard?" Archive: 2014 - Influenza A Variant Virus". cdc.gov.
- ^ Swaminathan K, Dyason JC, Maggioni A, von Itzstein M, Downard KM (2013). "Binding of a natural anthocyanin inhibitor to influenza neuraminidase by mass spectrometry". Anal Bioanal Chem. 405 (20): 6563–72. doi:10.1007/s00216-013-7068-x. PMID 23748498.
|
RNA virus antivirals (primarily J05, also S01AD and D06BB)
|
|
| Hepatitis C |
- protease inhibitors
- Asunaprevir†
- Boceprevir
- Faldaprevir‡
- Grazoprevir†
- Paritaprevir
- Simeprevir
- Telaprevir
- RNA polymerase inhibitors
- NS5A inhibitors
- Daclatasvir
- Elbasvir†
- Ledipasvir
- MK-3682
- MK-8408
- Odalasvir†
- Ombitasvir
- Ravidasvir†
- Samatasvir
- NS5B inhibitor
- Beclabuvir†
- Dasabuvir
- Deleobuvir§
- Filibuvir§
- Setrobuvir§
- Radalbuvir†
combinations (Ombitasvir/paritaprevir/ritonavir, Ledipasvir/sofosbuvir)
|
|
| Picornavirus |
|
|
| Anti-influenza agents |
- adamantane derivatives/M2 inhibitors (Amantadine
- Rimantadine)
- neuraminidase inhibitors/release phase (Oseltamivir
- Zanamivir
- Peramivir, Laninamivir†)
|
|
| Multiple/general |
| Interferon |
- Interferon alfa 2b
- Peginterferon alfa-2a#
|
|
| Multiple/unknown |
- BCX4430
- Favipiravir
- Moroxydine
- Ribavirin#/Taribavirin†
- Triazavirin
|
|
|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|
Index of viral disease
|
|
| Description |
|
|
| Disease |
- Systemic
- Cutaneous
- Zoster
- Human papillomavirus
- Zoonotic
- Symptoms and signs
|
|
| Treatment |
|
|
|
|
Pharmacology: enzyme inhibition
|
|
| Class |
- Competitive inhibition
- Uncompetitive inhibition
- Non-competitive inhibition
- Suicide inhibition
- Mixed inhibition
|
|
| Substrate |
| Oxidoreductase (EC 1) |
- 1.1 Aldose reductase
- HMG-CoA reductase
- 1.5 Dihydrofolate reductase
- 1.17 Xanthine oxidase
- Ribonucleotide reductase
|
|
| Transferase (EC 2) |
- 2.1 COMT
- Thymidylate synthase
- 2.5 Dihydropteroate synthetase
- Farnesyltransferase
- 2.7 Nucleotidyltransferase
- Integrase
- Reverse transcriptase
- Protein kinase
|
|
| Hydrolase (EC 3) |
- 3.1 Phosphodiesterase
- Acetylcholinesterase
- Ribonuclease
- 3.2 Polygalacturonase
- Neuraminidase
- Alpha-glucosidase
- 3.4 Protease: Exopeptidase
- Endopeptidase
- Mixed
- Enkephalinase
- Matrix metalloproteinase
- Oxytocinase
- 3.5 Histone deacetylase
- Beta-lactamase
|
|
| Lyase (EC 4) |
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- NAIplot: An opensource web tool to visualize neuraminidase inhibitor (NAI) phenotypic susceptibility results using kernel density plots.
- Lytras T1, Kossyvakis A2, Mentis A2.
- Antiviral research.Antiviral Res.2016 Feb;126:18-20. doi: 10.1016/j.antiviral.2015.12.002. Epub 2015 Dec 12.
- The results of neuraminidase inhibitor (NAI) enzyme inhibition assays are commonly expressed as 50% inhibitory concentration (IC50) fold-change values and presented graphically in box plots (box-and-whisker plots). An alternative and more informative type of graph is the kernel density plot, which w
- PMID 26692213
- The Hemagglutinin Stem-Binding Monoclonal Antibody VIS410 Controls Influenza Virus-Induced Acute Respiratory Distress Syndrome.
- Baranovich T1, Jones JC1, Russier M1, Vogel P2, Szretter KJ3, Sloan SE4, Seiler P1, Trevejo JM3, Webby RJ1, Govorkova EA5.
- Antimicrobial agents and chemotherapy.Antimicrob Agents Chemother.2016 Jan 19. pii: AAC.02457-15. [Epub ahead of print]
- Most cases of severe influenza are associated with pulmonary complications, such as acute respiratory distress syndrome (ARDS), and no antiviral drugs of proven value for treating such complications are currently available. The use of monoclonal antibodies targeting the stem of the influenza virus s
- PMID 26787699
- Outcomes and Susceptibility to Neuraminidase Inhibitors in Individuals Infected With Different Influenza B Lineages: The Influenza Resistance Information Study.
- van der Vries E1, Ip DK2, Cowling BJ2, Zhang JD3, Tong X4, Wojtowicz K5, Schutten M1, Boucher CA1.
- The Journal of infectious diseases.J Infect Dis.2016 Jan 15;213(2):183-90. doi: 10.1093/infdis/jiv375. Epub 2015 Jul 9.
- BACKGROUND: Little is known about how influenza infections caused by B/Victoria and B/Yamagata virus lineages compare with respect to disease course and susceptibility to antiviral therapy.METHODS: Data from patients with influenza B infections from the first 5 years (2009-2013) of the prospective I
- PMID 26160744
Japanese Journal
- 抗インフルエンザウイルス薬とその使い方 (特集 インフルエンザとその対策)
- 呼吸器内科医からみたインフルエンザ (特集 インフルエンザとその対策)
- Severe Immune Thrombocytopenia Possibly Elicited by the Anti-influenza Viral Agent Peramivir
Related Links
- Neuraminidase inhibitors are a class of drugs which block the neuraminidase enzyme. They are commonly used as antiviral drugs because they block the function of viral neuraminidases of the influenza virus, by preventing it's ...
- Neuraminidase inhibitor buibinhbaoson Subscribe Subscribed Unsubscribe 3 Loading... Loading... Working... Add to Want to watch this again later? Sign in to add this video to a playlist. Sign in Share More Report Need to 5 ...
★リンクテーブル★
[★]
- 英
- neuraminidase inhibitor, neuraminidase-inhibiting drug
- 関
- ノイラミニダーゼ阻害薬、インフルエンザ
[★]
- 英
- neuraminidase inhibitor
- 関
- ノイラミニダーゼ
[★]
ノイラミニダーゼ阻害薬
[★]
- 関
- abrogate、block、depress、depression、deter、inhibition、interdict、prevent、prevention、repress、repression、restrain、restraint、suppress、suppression
[★]
- 関
- blocker、depressant、suppressant